BMSON Header
보건의료전문가가 아닌 경우, 한국BMS Official Site (https://www.bms.com/kr)을 방문해 주세요.
Log Out My Profile Contact Us

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Oct 26, 2021

Error
Error
Success
Success
foot note heading
BMSON Footer